OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens

Article English OPEN
Aljayyoussi, Ghaith ; Kay, Katherine ; Ward, Stephen A. ; Biagini, Giancarlo A. (2016)
  • Publisher: BioMed Central
  • Journal: Malaria Journal, volume 15 (eissn: 1475-2875)
  • Related identifiers: doi: 10.13039/501100000265, doi: 10.1186/s12936-016-1401-8, pmc: PMC4936002
  • Subject: Infectious Diseases | qv_256 | Plasmodium | PK/PD modelling | DMPK | wc_765 | Malaria | Research | Pre-clinical | qv_38 | wc_750 | Artemisinin | Drug discovery | Pharmacokinetics | Lead optimisation | Medicinal chemistry | Parasitology | ADMET

BACKGROUND\ud The search for highly effective anti-malarial therapies has gathered pace and recent years have seen a number of promising single and combined therapies reach the late stages of development. A key drug development challenge is the need for early assessment of the clinical utility of new drug leads as it is often unclear for developers whether efforts should be focused on efficacy or metabolic stability/exposure or indeed whether the continuation of iterative QSAR (quantitative structure-activity and relationships) cycles of medicinal chemistry and biological testing will translate to improved clinical efficacy. Pharmacokinetic and pharmacodynamic (PK/PD)-based measurements available from in vitro studies can be used for such clinical predictions. However, these predictions often require bespoke mathematical PK/PD modelling expertise and are normally performed after candidate development and, therefore, not during the pre-clinical development phase when such decisions need to be made.\ud \ud METHODS\ud An internet-based tool has been developed using STELLA(®) software. The tool simulates multiple differential equations that describe anti-malarial PK/PD relationships where the user can easily input PK/PD parameters. The tool utilizes a simple stop-light system to indicate the efficacy of each combination of parameters. This tool, called OptiMal-PK, additionally allows for the investigation of the effect of drug combinations with known or custom compounds.\ud \ud RESULTS\ud The results of simulations obtained from OptiMal-PK were compared to a previously published and validated mathematical model on which this tool is based. The tool has also been used to simulate the PK/PD relationship for a number of existing anti-malarial drugs in single or combined treatment. Simulations were predictive of the published clinical parasitological clearance activities for these existing therapies.\ud \ud CONCLUSIONS\ud OptiMal-PK is designed to be implemented by medicinal chemists and pharmacologists during the pre-clinical anti-malarial drug development phase to explore the impact of different PK/PD parameters upon the predicted clinical activity of any new compound. It can help investigators to identify which pharmacological features of a compound are most important to the clinical performance of a new chemical entity and how partner drugs could potentially improve the activity of existing therapies.
  • References (40)
    40 references, page 1 of 4

    1. Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL, et al. Thousands of chemical starting points for antimalarial lead identification. Nature. 2010;465:305-10.

    2. Guiguemde WA, Shelat AA, Bouck D, Dufy S, Crowther GJ, Davis PH, et al. Chemical genetics of Plasmodium falciparum. Nature. 2010;465:311-5.

    3. Plouef D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K, et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci USA. 2008;105:9059-64.

    4. Burrows JN, van Huijsduijnen RH, Mohrle JJ, Oeuvray C, Wells TN. Designing the next generation of medicines for malaria control and eradication. Malar J. 2013;12:187.

    5. Austin DJ, White NJ, Anderson R. The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. J Theor Biol. 1998;194:313-39.

    6. Hoshen MB, Na-Bangchang K, Stein WD, Ginsburg H. Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of 'dormancy', a partial cytostatic eefct of the drug, and its implication for treatment regimens. Parasitology. 2000;121:237-46.

    7. Hoshen MB, Stein WD, Ginsburg H. Modelling the chloroquine chemotherapy of falciparum malaria: the value of spacing a split dose. Parasitology. 1998;116:407-16.

    8. Hoshen MB, Stein WD, Ginsburg H. Pharmacokinetic-pharmacodynamic modelling of the anti-malarial activity of mefloquine. Parasitology. 2001;123:337-46.

    9. Saralamba S, Pan-Ngum W, Maude RJ, Leea SJ, Tarning J, Lindegardh N, et al. Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci USA. 2011;108:397-402.

    10. Simpson JA, Watkins ER, Price RN, Aarons L, Kyle DE, White NJ. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother. 2000;44:3414-24.

  • Related Research Results (2)
  • Metrics
    No metrics available